Alcidion Group Ltd (ASX: ALC) Share Price and News

Price

$0.088

Movement

0.002 (+2.33%)

as at 13 May - Closed (20 mins delayed)

52 Week Range

$0.045 - $0.115

 
1 Year Return

+39.68%

Alcidion Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $115.49 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.34 billion
Earnings per share -0.004
Dividend per share N/A
Year To Date Return 45.00%
Earnings Yield N/A
Franking -
Share Price

$0.088

Day Change

0.002 (+2.33%)

52 Week Range

$0.045 - $0.115

Yesterday's Close

$0.086

Today's Open

$0.084

Days Range

$0.084 - $0.088

Volume

607,739

Avg. Volume (1 month)

1,361,735

Turnover

$52,121

as at 13 May - Closed

  • Alcidion Group Ltd (ASX: ALC)
    Latest News

    Two men cheering at laptop
    Opinions

    Skin in the game: The ASX share in my portfolio I'm most excited about

    Our Foolish writers spill the tea on the shares they own and have the highest hopes for.

    Read more »

    three children wearing superhero costumes, complete with masks, pose with hands on hips wearing capes and sneakers on a running track.
    Small Cap Shares

    3 battered small-cap ASX shares we're still backing: expert

    Smaller businesses saw their valuations tumble in a troubled year like 2022, but will likely rocket up higher and faster…

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Market News

    Top fund manager thinks ASX could start to move decisively higher, potentially sooner than you might be expecting

    Two ASX small cap stocks with material upside potential.

    Read more »

    A happy woman holding an umbrella in front of a rainbow.
    Best Shares

    Top ASX shares to buy in September 2022

    These are the stocks our Foolish writers think could be set to blossom in spring.

    Read more »

    a man sits at his computer screen scrolling with his fingers with a satisfied smile on his face as though he is very content with the news he is receiving.
    Earnings Results

    3 ASX All Ords shares lifting on full-year results

    It's been a good day so far for these companies delivering their earnings results on Tuesday.

    Read more »

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Alcidion, Betmakers, BrainChip, and Zip shares are racing higher

    These ASX shares are pushing higher on Wednesday...

    Read more »

    Five healthcare workers standing together and smiling.
    Technology Shares

    Alcidion share price surges 18% higher on record quarter

    Alcidion shares are on fire on Wednesday...

    Read more »

    A doctor and an elderly couple sit at a desk and look at a lung scan uploaded using Alcidion software as the Alcidion share price falls
    Ask a Fund Manager

    Buy and hold this 'incredibly undervalued' ASX share for 4 years: fundie

    Ask A Fund Manager: Cyan Investment Management's Dean Fergie is confused as to why this medical software business has been…

    Read more »

    A baby lying on a pile of one hundred dollar notes
    Small Cap Shares

    5 small-cap ASX shares sitting on a pile of cash: experts

    When interest rate fears bite, those who have their own money are king. Here are five such companies that Cyan…

    Read more »

    Two children hold on tightly to books hugged against their chests, as if they were holding on to ASX shares for the long term.
    Small Cap Shares

    2 ASX shares we're sticking with after 60% falls: fund managers

    Stock prices are now 'extremely attractive', say portfolio managers that are focusing on the long term for their small-cap fund.

    Read more »

    A man watches the share price movement closely.
    Small Cap Shares

    3 exciting small cap ASX shares to watch

    Check out these highly rated small cap ASX shares...

    Read more »

    A businessman hugs his computer and smiles.
    Broker Notes

    4 fallen ASX shares that are still awesome businesses: expert

    World events are taking stock prices down, but many businesses are still going as strong as ever. Here are some…

    Read more »

    Frequently Asked Questions

    ALC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    22nd Apr 2025 2025-04-22T08:22:59 Q3 FY25 Quarterly Activities Report and Appendix 4CYesNo8:22am8562k
    16th Apr 2025 2025-04-16T11:21:47 Alcidion Q3 FY25 Results and Investor Webcast NotificationYesNo11:21am2158k
    16th Apr 2025 2025-04-16T11:12:57 Notification regarding unquoted securities - ALCYesNo11:12am616k
    15th Apr 2025 2025-04-15T08:27:25 Initial Director's Interest NoticeYesNo8:27am3317k
    15th Apr 2025 2025-04-15T08:21:00 Appointment of Non-Executive DirectorYesNo8:21am2184k
    12th Mar 2025 2025-03-12T08:18:33 Investor Roadshow PresentationYesNo8:18am374.4M
    7th Mar 2025 2025-03-07T08:21:46 Coffee Microcaps PresentationYesNo8:21am192.1M
    4th Mar 2025 2025-03-04T16:19:43 Change of Director's Interest NoticeYesNo4:19pm2163k
    4th Mar 2025 2025-03-04T16:15:23 Share Sale by Managing Director & CEOYesNo4:15pm1133k
    27th Feb 2025 2025-02-27T20:28:38 Ceasing to be a substantial holderYesNo8:28pm2139k

    About Alcidion Group Ltd

    Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.

    The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.

    Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems.  Other products include Smartpage and Patientrack software.

    Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.

    ALC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    12 May 2025 $0.09 $0.00 0.00% 665,182 $0.08 $0.09 $0.08
    09 May 2025 $0.09 $0.00 0.00% 1,806,840 $0.08 $0.09 $0.08
    08 May 2025 $0.08 $0.00 0.00% 724,118 $0.08 $0.08 $0.08
    07 May 2025 $0.08 $0.00 0.00% 1,741,852 $0.08 $0.08 $0.08
    06 May 2025 $0.08 $0.00 0.00% 550,898 $0.08 $0.09 $0.08
    05 May 2025 $0.08 $0.00 0.00% 792,442 $0.09 $0.09 $0.08
    02 May 2025 $0.09 $0.00 0.00% 2,154,403 $0.09 $0.09 $0.08
    01 May 2025 $0.09 $0.00 0.00% 612,702 $0.09 $0.09 $0.08
    30 Apr 2025 $0.09 $0.00 0.00% 1,620,946 $0.09 $0.09 $0.09
    29 Apr 2025 $0.09 $0.00 0.00% 2,765,729 $0.08 $0.09 $0.08
    28 Apr 2025 $0.08 $0.00 0.00% 1,157,889 $0.08 $0.09 $0.08
    24 Apr 2025 $0.08 $0.00 0.00% 1,458,843 $0.09 $0.09 $0.08
    23 Apr 2025 $0.08 $0.00 0.00% 1,773,212 $0.08 $0.09 $0.08
    22 Apr 2025 $0.08 $0.00 0.00% 3,251,333 $0.08 $0.09 $0.08
    17 Apr 2025 $0.08 $0.00 0.00% 1,316,903 $0.08 $0.08 $0.07
    16 Apr 2025 $0.08 $0.00 0.00% 908,707 $0.07 $0.08 $0.07
    15 Apr 2025 $0.07 $0.00 0.00% 709,027 $0.08 $0.08 $0.07
    14 Apr 2025 $0.08 $0.00 0.00% 500,207 $0.07 $0.08 $0.07

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Mar 2025 Katrina (Kate) Doyle (Quirke) Sell 5,000,000 $425,000
    Off-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Rebecca Jayne Wilson Non-Executive DirectorNon-Executive Chairman Jul 2017
    Ms Wilson is a company director and Board advisor in Australia, UK and US and has more than 25 years of experience working within the healthcare, technology and life science sectors. She provides advice on complex stakeholder communication, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She has mature governance and risk management experience.
    Mr William (Bill) Smart Non-Executive Director Oct 2024
    Mr Smart is a global digital health leader at both an operational and non-executive level having recently stepped down as the Global Director of External Relations, Dedalus Group, a global digital health company. Based in the United Kingdom, Will is currently Digital Non-Executive Director, Great Western Hospitals NHS Foundation Trust and was previously the CIO for Health and Social Care for England. He has held executive roles in several NHS Trusts including as Group Chief Information Officer, Royal Free London NHS Foundation Trust. In his capacity as Digital Non-Executive Director, Great Western Hospitals NHS Foundation Trust, Will is a member of the Acute Hospitals Alliance EPR Joint Committee responsible for overseeing the implementation of a new EPR across Great Western, Royal University Hospital, and Salisbury Trusts. Will is also a Director of CareTech Partners Limited providing digital advisory and consultancy support to public and private organisations and a member of the Health and Social Care Council at TechUK, a member organisation that represents and supports the UK technology sector and works with government, regulators and stakeholders.
    Ms Victoria Weekes Non-Executive Director Sep 2021
    Ms Weekes is a non-executive director with experience across a diverse range of industries built on a successful executive career in investment markets and financial services. Victorias 30 years of experience in the finance and banking sector includes Csuite roles as a Managing Director at Citigroup and Executive General Manager at Westpac. As the immediate past Chair of the Sydney Local Health District, Victoria has a deep understanding of the healthcare sector where she served as Chair of its Education & Research Committee and Deputy Chair. She is the chairman of risk committee.
    Ms Katrina (Kate) Elizabeth Doyle (Quirke) Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Ms Doyle has been CEO of Alcidion since 2018, prior to which she was CEO of MKM Health until it was acquired by Alcidion. She has been involved in large systems procurements and implementations of healthcare information technology across Australia, United Kingdom, New Zealand and Southeast Asia. Her background involves holding leading management roles at some of the largest healthcare software firms where she has had an impact on strategic product direction across
    the health sector and believes astute application of information technology will support the transformation of healthcare delivery worldwide.
    Mr Daniel Sharp Non-Executive Director Sep 2021
    Mr Sharp has over 25 years senior executive experience in investment banking and corporate finance. From 2012-2020, Daniel was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Daniel headed the corporate finance division at two of Australia's independent Investment Banking/Stockbroking firms. He is closely connected to strong networks of institutional, family office and high net worth investors both in Australia and overseas. He is also a member of risk committee.
    Professor Andrew Way Non-Executive Director Apr 2025
    Prof Way brings a wealth of experience to the Board of Alcidion, having served as the Chief Executive of Alfred Health from 2009 to 2024 as well as having held several senior positions in the England National Health Service (NHS). Andrew also led the development of Monash Partners, Victorias first Academic Health Science Centre and was appointed as an Adjunct Clinical Professor in the School of Public Health and Preventative Medicine, Faculty of Medicine Nursing and Health Sciences, Monash University in 2015. In addition to his senior leadership roles, Professor Way holds several non-executive and advisory roles both in Australia and internationally including Chair of the Department of Healths HSV (Health Services Victoria) Board.
    Mr Michael Sapountzis Company Secretary Mar 2019
    -
    Matthew Gepp Chief Financial Officer
    -
    Michael Sapountzis Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 156,589,750 11.66%
    Mr Malcolm Pradhan 134,582,403 10.02%
    Bond Street Custodians Limited <Salter D79836 A/C> 73,000,000 5.44%
    Mr Raymond Howard Blight 68,801,020 5.12%
    Rewmicman Pty Ltd <Smallman Family A/C> 28,810,441 2.15%
    Mrs Katrina Elizabeth Doyle 27,793,199 2.07%
    Caledonia Nominees Pty Ltd <Caledonia A/C> 19,976,377 1.49%
    MNMD Pty Ltd <Quirke Super Fund A/C> 19,668,086 1.47%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 17,189,236 1.28%
    Bond Street Custodians Limited <RSALTE - D62375 A/C> 13,999,000 1.04%
    Mr Dean Anthony Mackenzie 13,143,801 0.98%
    Mr Paul John Van Dyk 12,300,000 0.92%
    Sandhurst Trustees Ltd <Cyan C3G Fund A/C> 10,469,114 0.78%
    Citicorp Nominees Pty Limited 10,272,574 0.77%
    Rangiora London Pty Limited <Rangiora-London A/C> 7,800,000 0.58%
    Emerald Shares Pty Limited <Emerald Unit A/C> 7,100,000 0.53%
    Mr Vivek Ramakrishnan and Miss Nisha Srinivasan 7,021,913 0.52%
    Finclear Services Pty Ltd <Superhero Securities A/C> 6,807,539 0.51%
    Hudson Retirement Pty Ltd <Seagulls Super A/C> 6,524,244 0.49%
    Webzone Holdings Pty Ltd 5,820,000 0.42%

    Profile

    since

    Note